share_log

葫芦娃(605199.SH):酒石酸阿福特罗雾化吸入用溶液获得药物临床试验批准通知书

Hainan Huluwa Pharmaceutical Group (605199.SH): The clinical trial approval notice for Afutelow inhalation solution of tartaric acid has been obtained.

Gelonghui Finance ·  Jul 23 05:40

Hainan Huluwa Pharmaceutical Group (605199.SH) announced on July 23 that it has recently received the "Drug Clinical Trial Approval Notice" issued and approved by the National Medical Products Administration regarding the aerosol inhalation solution of afoterol tartrate, authorizing the conduct of clinical trials for the product. Afoterol tartrate aerosol inhalation solution is suitable for the long-term treatment of bronchial constriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment